Antibody Sequencing Service

KMD Bioscience can provide 100% accurate antibody sequencing services based on ultra-high resolution mass spectrometry and high-fidelity gene cloning technology.

 

Monoclonal antibody molecules play a key role in drug development and diagnostic reagent development. The primary structure of the antibody molecule, especially the amino acid sequence of its CDR region is the core of its biological function, and its accurate and rapid analysis of the complete sequence is of great significance. KMD Bioscience uses the most advanced Orbitrap Fusion Lumos mass spectrometer and powerful antibody sequencing data processing software: PEAKS AB Software, combined with gene sequencing and bioinformatics database, established a new generation of antibody sequencing platform to achieve fast and accurate antibody primary structure. The analysis thus ensures the accuracy of each antibody sequencing. Our platform is suitable for different subtypes of antibodies such as IgA, IgE, IgG and IgM, as well as different forms of antibodies, such as fluorescently coupled antibodies, immobilized antibodies, and it's suitable for different species.

 

Project Features:

*Design and finish LC-MS/MS analysis with only 200ug antibody

*De novo protein sequencing technology based on protein database

*Applicable to all species of antibodies and different antibody subtypes

*Direct quantitative post-transcriptional modification and variant sequences

*Results within 14 days

 

Service Highlights:

---100% Accuracy

Our sequencing services perform strict quality control and use the principle of wide-in and narrow-out to achieve accurate identification of antibody sequences without missing any valid data information. The Orbitrap Fusion Lumos mass spectrometer currently used in our laboratory, compared to the previous generation Orbitrap Elite mass spectrometer, Lumos improves the accuracy of the molecular weight of the peptide while improving the scanning speed of the primary and secondary mass spectrometry. Combined with our industry benchmark logic algorithms and powerful processing capabilities (based on PEAKS software analysis), our antibody sequencing platform makes it difficult to distinguish amino acids with similar molecular weights from traditional techniques, such as achieving molecular weight differences of 0.03Da. Differential analysis of glutamine and lysine.

 

 

---100% Sequence Coverage

KMD Bioscience uses up to 8 different proteases to digest the target antibody for different project needs, and uses PEAKS software to automatically achieve 100% complete sequence splicing between different light and heavy chain fragments. For the antibody complementarity determining region (CDR region), a peptide sequence containing a single site is generated 10 times at least, and high coverage is ensured to ensure accurate splicing of subsequent antibody sequences.

 

 

---Powerful Modification Analysis Capabilities

Our antibody sequencing platform can efficiently distinguish different variants of homologous amino acids, and the accurate determination of leucine and isoleucine can be achieved by the characteristic peaks of the secondary fragment. Our system can also be distinguished efficiently for post-transcriptionally modified amino acid molecules. It's suitable for sequencing with fluorescently labeled monoclonal antibodies, IgMs, and other non-traditional antibodies. Our antibody sequencing technology can also perform small-group sequencing efficiently, such as FITC, Biotin, Alexa and other labeled antibodies. By increasing the amount of antibody, we can also perform antibodies similar to large protein groups such as GST. Sequencing work. Our technology is suitable for any type of antibody sequencing work, and we have successfully sequenced antibodies from mice, rabbits, alpacas, hamsters and sheep. In practice, IgM sequencing methods are similar to IgG, except that the former requires more protein samples.

 

---Strict Sequence Prediction and Strict Sequence Verification

For each antibody sequencing project, we will give specific experimental protocols. First, we will perform sequence prediction on the target antibody. If the customer provides hybridomas, we can also perform antibody sequencing and then combine mRNA sequencing information to ensure the accuracy of single amino acid sequencing of the antibody. Meanwhile, we will also establish a database based on the sequence, and use the sequence confirmation mode to perform a second comparison analysis of the collected mass spectrometry data to ensure that the delivered product is completely correct.